Psychiatric diagnosis

Neuronetics to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call

Retrieved on: 
Tuesday, July 20, 2021
Psychiatry, Branches of biology, Mind, Abnormal psychology, Mental disorder, Psychiatric assessment, Psychiatric diagnosis, Psychopathology, Suffering

MALVERN, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc.(NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release second quarter financial and operating results prior to market open on Tuesday, August 3, 2021.

Key Points: 
  • MALVERN, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc.(NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release second quarter financial and operating results prior to market open on Tuesday, August 3, 2021.
  • The Company will host a conference call to review its results at8:30 a.m. Eastern Timethe same day.
  • The conference call will be broadcast live in listen-only mode via a webcast on the Companys investor relations website at ir.neuronetics.com .
  • Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders.

KeifeRx Receives FDA Acceptance of Investigational New Drug for Phase 3 Study of Nilotinib BE in Early Alzheimer's Disease

Retrieved on: 
Tuesday, July 20, 2021
Psychiatry, Cognitive disorders, Branches of biology, Learning disabilities, Psychiatric diagnosis, Neuroscience, Dementia, Orphan drugs, Nilotinib, Alzheimer's disease

The safety and efficacy of a Nilotinib BE will be investigated in individuals with dementia due to Alzheimer's disease with abnormal levels of brain amyloid and supporting clinical diagnosis of early Alzheimer's disease.

Key Points: 
  • The safety and efficacy of a Nilotinib BE will be investigated in individuals with dementia due to Alzheimer's disease with abnormal levels of brain amyloid and supporting clinical diagnosis of early Alzheimer's disease.
  • "Our Phase 3 study provides us the opportunity to gain valuable insights about the potential effectiveness of Nilotinib BE in treating early Alzheimer's.
  • KeifeRx will launch a national, multicenter, placebo-controlled, double-blind study of Nilotinib BE in early Alzheimer's disease.
  • The primary objectives of the study are to investigate the safety and efficacy of Nilotinib BE on the progression of dementia in early Alzheimer's disease.

Mindset Pharma Announces Appointment of Clinician Scientist, Dr. Ishrat Husain, to Scientific Advisory Board

Retrieved on: 
Tuesday, July 20, 2021
Psychiatry, Psychiatric diagnosis, Mood disorders, Psychopathology, Depression, Abnormal psychology, Mental disorder, Bipolar disorder

Dr. Ishrat Husain is at the forefront of research into the neurobiology of depression and bipolar disorder, and currently conducting clinical trials of emerging treatments for these conditions.

Key Points: 
  • Dr. Ishrat Husain is at the forefront of research into the neurobiology of depression and bipolar disorder, and currently conducting clinical trials of emerging treatments for these conditions.
  • Dr. Husain has published over 40 research papers investigating the neurobiology and associated clinical care of mood disorders.
  • Dr. Husains appointment is another important milestone in our journey to bring safer, more efficacious psychedelic-inspired mental illness treatments to the market.
  • Mindset was established in order to develop pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Braxia Scientific Secures Approval for Direct Billing Insurance on Ketamine Treatments for Veterans Affairs Canada Clients

Retrieved on: 
Tuesday, July 20, 2021
Psychoactive drugs, Psychiatry, Drugs, Psychiatric diagnosis, Abnormal psychology, Chloroarenes, Nicotinic antagonists, Sedatives, Ketamine, Depression, Psilocybin, Major depressive disorder

Braxia Scientific , is a medical research Company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Key Points: 
  • Braxia Scientific , is a medical research Company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
  • Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.
  • Braxia develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.
  • The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Dr. Jay's Naturals Selects The Birdwell Foundation For PTSD As Primary Charity Recipient

Retrieved on: 
Tuesday, July 20, 2021
Aftermath of war, Military personnel, Veterans' affairs, Medical specialties, Psychiatry, Military, Military psychiatry, Post-traumatic stress disorder, Psychiatric diagnosis, Veteran, Birdwell, Jay's

HOUSTON, July 20, 2021 /PRNewswire/ -- Mr. Gene Birdwell, majority stockholder of Dr. Jay's Naturals, announces adoption of the Birdwell Foundation for PTSD as the charitable recipient of 20% of profits from Dr. Jay's proprietary products.

Key Points: 
  • HOUSTON, July 20, 2021 /PRNewswire/ -- Mr. Gene Birdwell, majority stockholder of Dr. Jay's Naturals, announces adoption of the Birdwell Foundation for PTSD as the charitable recipient of 20% of profits from Dr. Jay's proprietary products.
  • Dr. Jay's Naturals would like to inspire other businesses and individuals to support the Birdwell Foundation for PTSD 's work on behalf of those suffering PTSD and related illnesses.
  • Helping Birdwell reach, serve and help restore more veterans and first responders is consistent with the mission of Dr. Jay's Naturals ( https://drjaysnaturals.com ).
  • Even more PTSD suffers can be reached if more companies and product lines follow suit and support the Foundation.

Lyndra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other Indications

Retrieved on: 
Monday, July 19, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Psychiatry, Drugs, Abnormal psychology, Psychiatric diagnosis, Atypical antipsychotics, Mood stabilizers, Depression, Mood disorders, Risperidone, Bipolar disorder, Schizophrenia, Bipolar I disorder

The company plans to initiate its pivotal program for LYN-005, designed as the first-ever oral, ultra-long-acting, extended-release therapy, in early 2022.

Key Points: 
  • The company plans to initiate its pivotal program for LYN-005, designed as the first-ever oral, ultra-long-acting, extended-release therapy, in early 2022.
  • Both studies will evaluate LYN-005 at weekly doses ranging from 2 to 6 mg risperidone daily.
  • These studies will support indications in schizophrenia, bipolar mania, and bipolar 1 disorder.
  • We are grateful to the FDA for their guidance as we design this pivotal program.

Receptor Life Sciences Announces Initiation of IND-Opening Clinical PK Study of RLS102 for Irritability in Autism Spectrum Disorder

Retrieved on: 
Monday, July 19, 2021
Health, FDA, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Psychiatric diagnosis, Psychiatry, Neuroscience, Autism, Developmental neuroscience, Developmental psychology, Learning disabilities, Autism spectrum, Irritability, Developmental disorder, Autism therapies

This first-in-class, pure synthetic CBD capsule is being investigated for the treatment of irritability in patients with autism spectrum disorder.

Key Points: 
  • This first-in-class, pure synthetic CBD capsule is being investigated for the treatment of irritability in patients with autism spectrum disorder.
  • Following the IND acceptance, RLS initiated a pharmacokinetic (PK), formulation selection study using RLS102 in healthy volunteers.
  • RLS102 has the potential to be a new treatment to reduce irritability in patients living with autism spectrum disorder, said Mark Theeuwes, President and CEO, Receptor Life Sciences.
  • A complex developmental disorder often associated with a high level of irritability, autism spectrum disorder (ASD) affects about 5 million adults in the United States ( https://www.cdc.gov/ncbddd/autism/features/adults-living-with-autism-spe... ).

Join the Race to End Alzheimer's by Featuring Your Loved One's Name On a Competitive Sports Car

Retrieved on: 
Saturday, July 17, 2021
Branches of biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Neuroscience, Psychiatry, Abnormal psychology, Alzheimer's disease, Dementia

The foundation has created a simple and meaningful process for people to support that "race" while also honoring their friends and family members.

Key Points: 
  • The foundation has created a simple and meaningful process for people to support that "race" while also honoring their friends and family members.
  • In 2017, Racing to End Alzheimer's began as a passion project for Frengs when his wife Mimi was diagnosed with early-onset Alzheimer's.
  • Frengs and the team behind Racing to End Alzheimer's have made the process of getting your loved one's name on a race car as easy as possible.
  • Learn more about Racing to End Alzheimer's or donate to remember your loved one on their website , r2endalz.org .

Caravel Autism Health Opens Third Autism Therapy Center for Families in the Treasure Valley

Retrieved on: 
Friday, July 16, 2021
Branches of biology, Psychiatric diagnosis, Psychiatry, Neuroscience, Autism, Pervasive developmental disorders, Learning disabilities

"ABA therapy is critically important for children who are on the autism spectrum," according to Anna McLane, MA, BCBA, clinical director for Caravel Autism Health in Meridian.

Key Points: 
  • "ABA therapy is critically important for children who are on the autism spectrum," according to Anna McLane, MA, BCBA, clinical director for Caravel Autism Health in Meridian.
  • By bringing three new autism therapy centers to the Treasure Valley, we have significantly expanded local availability and access to high-quality autism services.
  • Prior to opening the Meridian center, Caravel established autism therapy centers in Boise and Nampa earlier this year.
  • Since 2009, Caravel Autism Health has been devoted to helping families navigate the challenges of childhood autism.

Caregiver Action Network Announces New Digital Tool for Caregivers of Loved Ones With Dementia

Retrieved on: 
Wednesday, July 14, 2021
Health, Human behavior, Psychiatric diagnosis, Caregiving, Aging-associated diseases, Cognitive disorders, Dementia, Caregiver, Family caregivers, Caring for people with dementia, Caregiver stress

Washington, DC, July 14, 2021 (GLOBE NEWSWIRE) -- Caregivers of loved ones with dementia are about to get more help thanks to Caregiver Action Network (CAN) .

Key Points: 
  • Washington, DC, July 14, 2021 (GLOBE NEWSWIRE) -- Caregivers of loved ones with dementia are about to get more help thanks to Caregiver Action Network (CAN) .
  • CAN is launching a new digital tool, Lighting Your Way: Dealing With the Behavioral Symptoms of Your Loved Ones Dementia , to help caregivers better understand some of the symptoms that can accompany dementia and what can be done about them.
  • Lighting Your Way: Dealing With the Behavioral Symptoms of Your Loved Ones Dementia provides information specifically tailored to family caregivers of those diagnosed with dementia in five sections.
  • For more details, please visit Lighting Your Way: Dealing With the Behavioral Symptoms of Your Loved Ones Dementia .